The diagnostic value of sST2 for myocardial fibrosis in idiopathic inflammatory myopathies in subclinical stage of cardiac involvement
Authors' conclusion
sST2 showed a marked elevation during the subclinical stage of cardiac involvement in IIM and has potential as a biomarker for predicting diffuse and focal myocardial fibrosis in IIM.
Study context
- Population
- IIM patients with normal heart function (subclinical stage of cardiac involvement); myocardial fibrosis assessed by cardiac MRI
- Participants
- 44 vs 32
- Comparison
- IIM patients with normal heart function vs healthy controls
- IIMn = 44
- Healthy controls (HCs)n = 32reference
- Outcome
- Diagnostic value of serum sST2 (ELISA) for myocardial fibrosis (native T1, ECV, LGE on cardiac MRI)
Methodological detailsage- and gender-matched healthy controls
- Age- and gender-matched healthy controls
Performance
As reported in the abstract
sST2 for diagnosing myocardial fibrosis
Estimate (95% CI)P value
sST2 (per unit increase)
OR, diffuse myocardial fibrosis 1.154(1.021–1.305)
P = 0.022sST2 (per unit increase)
OR, focal myocardial fibrosis 1.038(1.006–1.072)
P = 0.020Per unit increase, as printed
Further findings
| Outcome | IIM | P value |
|---|---|---|
| Serum sST2 levels | 67.5 (SD 30.4) ng/ml | P < 0.001 |
Serum sST2 levels
- IIM patients had significantly higher sST2 levels than HCs
Correlation of sST2 with cardiac magnetic resonance (CMR) fibrosis parameters (Spearman)
- Native T1, r (P = 0.000)
- 0.531
- Extracellular volume (ECV), r (P = 0.013)
- 0.371
- Focal myocardial fibrosis index and late-gadolinium enhancement (LGE), r (P = 0.024)
- 0.339
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
The diagnostic value of sST2 for myocardial fibrosis in idiopathic inflammatory myopathies in subclinical stage of cardiac involvement. Rheumatology (Oxford). Published 24 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →